TY - JOUR
T1 - Leveraging Comprehensive Cancer Registry Data to Enable a Broad Range of Research, Audit and Patient Support Activities
AU - Lee, Belinda
AU - Gately, Lucy
AU - Lok, Sheau Wen
AU - Tran, Ben
AU - Lee, Margaret
AU - Wong, Rachel
AU - Markman, Ben
AU - Dunn, Kate
AU - Wong, Vanessa
AU - Loft, Matthew
AU - Jalili, Azim
AU - Anton, Angelyn
AU - To, Richard
AU - Andrews, Miles
AU - Gibbs, Peter
N1 - Funding Information:
Ben Tran reports grants and personal fees from Amgen, AstraZeneca, BMS, Janssen, Pfizer, MSD, Ipsen, Bayer; grants from Astellas, personal fees from IQVIA, Roche, Sanofi, Tolmar and Novartis. Angelyn Anton reports research funding from Astellas, Amgen, AstraZenecca, Janssen and Mundipharma and honoraria from Janssen and Amgen. Venessa Wong reports honoraria from Amgen, and research funding from Amgen, Novartis, Merck, Roche, Pierre Fabre and AstraZeneca. All other authors declare no conflict of interest.
Publisher Copyright:
© 2022 by the authors.
PY - 2022/9
Y1 - 2022/9
N2 - Traditional cancer registries have often been siloed efforts, established by single groups with limited objectives. There is the potential for registry data to support a broad range of research, audit and education initiatives. Here, we describe the establishment of a series of comprehensive cancer registries across the spectrum of common solid cancers. The experience and learnings of each registry team as they develop, implement and then use collected data for a range of purposes, that informs the conduct and output of other registries in a virtuous cycle. Each registry is multi-site, multi-disciplinary and aims to collect data of maximal interest and value to a broad range of enquiry, which would be accessible to any researcher with a high-quality proposal. Lessons learnt include the need for careful and continuous curation of data fields, with regular database updates, and the need for a continued focus on data quality. The registry data as a standalone resource has supported numerous projects, but linkage with external datasets with patients in common has enhanced the audit and research potential. Multiple projects have linked registry data with matched tissue specimens to support prognostic and predictive biomarker studies, both validation and discovery. Registry-based biomarker trials have been successfully supported, generating novel and practice-changing data. Registry-based clinical trials, particularly randomised studies exploring the optimal use of available therapy options are now complementing the research conducted in traditional clinical trials. More recent projects supported by the registries include health economic studies, personalised patient education material, and increased consumer engagement, including consumer entered data.
AB - Traditional cancer registries have often been siloed efforts, established by single groups with limited objectives. There is the potential for registry data to support a broad range of research, audit and education initiatives. Here, we describe the establishment of a series of comprehensive cancer registries across the spectrum of common solid cancers. The experience and learnings of each registry team as they develop, implement and then use collected data for a range of purposes, that informs the conduct and output of other registries in a virtuous cycle. Each registry is multi-site, multi-disciplinary and aims to collect data of maximal interest and value to a broad range of enquiry, which would be accessible to any researcher with a high-quality proposal. Lessons learnt include the need for careful and continuous curation of data fields, with regular database updates, and the need for a continued focus on data quality. The registry data as a standalone resource has supported numerous projects, but linkage with external datasets with patients in common has enhanced the audit and research potential. Multiple projects have linked registry data with matched tissue specimens to support prognostic and predictive biomarker studies, both validation and discovery. Registry-based biomarker trials have been successfully supported, generating novel and practice-changing data. Registry-based clinical trials, particularly randomised studies exploring the optimal use of available therapy options are now complementing the research conducted in traditional clinical trials. More recent projects supported by the registries include health economic studies, personalised patient education material, and increased consumer engagement, including consumer entered data.
KW - big data
KW - cancer registry
KW - data-driven research
KW - digital health
KW - registry-based trials
UR - http://www.scopus.com/inward/record.url?scp=85137788845&partnerID=8YFLogxK
U2 - 10.3390/cancers14174131
DO - 10.3390/cancers14174131
M3 - Review Article
C2 - 36077668
AN - SCOPUS:85137788845
SN - 2072-6694
VL - 14
JO - Cancers
JF - Cancers
IS - 17
M1 - 4131
ER -